Find your next paid study

Nurix Therapeutics, Inc.NCT05107674

Actual pay is set by the research site.

Phase 3

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment

The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have prog…

Metastatic Castration-resistant Prostate Cancer

Telix Pharmaceuticals (Innovations) Pty LimitedNCT06520345

~$50 – $2,100

Actual pay is set by the research site.

Advanced Solid TumorDiffuse Large B Cell LymphomaLymphoma, T-Cell+5 more

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitum…

Novartis PharmaceuticalsNCT04104776

Actual pay is set by the research site.

Cervical CancerBreast CancerColon Cancer+4 more

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants With Recurrent or Metastatic GRPR-expressing Tumors

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary E…

Orano Med Theranostics, SASNCT05283330

~$150 – $4,500

Actual pay is set by the research site.

mCRPC (Metastatic Castration-resistant Prostate Cancer)Prostate Cancer

PATHWAY: A Phase 1b/2a, Multicenter, Open- Label Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic cast…

Pathos AI, Inc.NCT06785636

Actual pay is set by the research site.

Phase 2

A Phase 2 Study of Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Metastatic Castration Resistant Prostate Cancer

This is a single-center, open-label, study of Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapy with 177Lu-PSMA-617 in combination with p…

Castrate Resistant Prostate CancerMetastatic Castration-resistant Prostate CancerProstate Cancer+1 more

University of California, San FranciscoNCT05766371

~$75 – $1,800

Actual pay is set by the research site.

Esophageal Squamous Cell CarcinomaHigh Grade Serous Ovarian CancerHead and Neck Squamous Cell Carcinoma+5 more

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary eff…

IDEAYA BiosciencesNCT07503808

Actual pay is set by the research site.

Phase 2

A Single Arm Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) With Soft Tissue or Visceral Metastases

This research study is for people with metastatic castrate-resistant prostate cancer (mCRPC). Zanzalintinib is a new drug that shows activity in mCRPC with sof…

Metastatic Castration-resistant Prostate Cancer

Pedro Barata, MD, MScNCT07608718

~$75 – $3,000

Actual pay is set by the research site.

Prostate Cancer Castration-resistant Prostate CancerBreast CancerColo-rectal Cancer+2 more

A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors

This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumor…

MBrace TherapeuticsNCT07145255

Actual pay is set by the research site.

Prostate CancerMetastatic Castration-resistant Prostate CancerCastration Resistant Prostatic Cancer

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the …

Janux TherapeuticsNCT05519449

Actual pay is set by the research site.

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer

An Open-label, Multi-center, Phase I/II Study of GVV858 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer and Other Advanced Solid Tumors

Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimizatio…

Novartis PharmaceuticalsNCT07288359

Actual pay is set by the research site.

Metastatic Castration-resistant Prostate Cancer

A Phase 1, Multicenter Trial Evaluating the Safety, Tolerability, and Efficacy of Valemetostat (DS-3201) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prosta…